Clinical Trials
Stemedica announces clinical trial for IV stem cell treatment for chronic ischemic stroke
Stemedica Cell Technologies announced the launch of a phase 2b/3 clinical trial to assess the safety, efficacy and tolerability of a single IV injection of allogenic mesenchymal stem cells in patients with chronic ischemic stroke.
FDA grants fast track designation for facioscapulohumeral muscular dystrophy treatment
The FDA has granted fast track designation to Avidity Biosciences Inc. for its novel RNA therapeutic AOC 1020, an antibody oligonucleotide conjugate being studied for the treatment of facioscapulohumeral muscular dystrophy.
Race linked to survival disparities in head and neck cancer trials
Black patients in head and neck cancer clinical trials consistently achieved poorer survival than white patients who received the same treatments, according to study results.
Treatment with nusinersen improved motor function up to 5 years in infantile-onset SMA
Treatment with nusinersen led to continued and improved motor function up to 5 years after initial dose in infants with spinal muscular atrophy, according to a poster presented at the International Scientific Congress on Spinal Muscular Atrophy.
Positive topline results shown in clinical trial of adolescent ADHD treatment
A digital medicine company has revealed positive topline results of an expansionist study evaluating the efficacy and safety of a novel therapeutic device to treat adolescents with ADHD.
First participants enrolled in phase 3 trial for early AD therapeutic
AriBio USA Inc. announced the enrollment of the first participants in a phase 3 trial to evaluate the efficacy of a novel therapeutic to treat those with early Alzheimer’s disease.
Racial, ethnic minority groups lack representation in OB/GYN trials
Reporting of race and ethnicity data and representation of different racial and ethnic populations in OB/GYN clinical trials are subpar, although improvement is possible, according to findings published in JAMA Surgery.
Partnership to initiate phase 1/2a clinical trial for AD dementia vaccine
A biopharmaceutical company and the Miller School of Medicine at the University of Miami have announced a partnership to conduct a phase 1/2a clinical trial of ALZN002, a treatment for Alzheimer’s-related dementia.
Phase 2a study initiated to examine synthetic DMT for treatment-resistant depression
A biotech company based in the U.K. announced that it has initiated a phase 2a study for BPL-003for treatment-resistant depression.
County poverty rate linked to multiple myeloma clinical trial availability
A county’s poverty rate appeared significantly associated with the likelihood it would be home to at least one registered multiple myeloma clinical trial site, according to study results.